PITAVASTATIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H24FNO4
Molecular Weight	421.4608
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4)CC(O)=O

InChI

InChIKey=VGYFMXBACGZSIL-MCBHFWOFSA-N

InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H24FNO4
Molecular Weight	421.4608
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical
Record UNII	M5681Q5F9P
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

PITAVASTATIN

Official Name

English

PITAVASTATIN [MI]

Common Name

English

pitavastatin [INN]

Common Name

English

PITAVASTATIN [MART.]

Common Name

English

Pitavastatin [WHO-DD]

Common Name

English

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

HMG CoA reductase inhibitors

WHO-VATC

QC10AA08

Established Pharmacologic Class

NDF-RT

N0000175589

lipid lowering agent

LIVERTOX

NBK548065

Enzyme Inhibitor

NCI_THESAURUS

C1655

HMG CoA reductase inhibitors

WHO-ATC

C10AA08

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

INN

7730

PRIMARY

HSDB

8367

PRIMARY

CHEBI

32020

PRIMARY

RXCUI

861634

PRIMARY

RxNorm

WIKIPEDIA

PITAVASTATIN

PRIMARY

Showing 1 to 5 of 21 entries

Previous1 2 3 4 5Next

Show entries

Related Record

Type

Details


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> INHIBITOR


					29556RBN9P

PITAVASTATIN SODIUM

SALT/SOLVATE -> PARENT


					IYD54XEG3W

PITAVASTATIN CALCIUM

SALT/SOLVATE -> PARENT

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:

[99.5 to 99.6] % (average)


					GMK323785E

PITAVASTATIN CALCIUM PENTAHYDRATE

SALT/SOLVATE -> PARENT

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					VSZ43HE9FC

(3R,6E)-7-(2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-3-QUINOLINYL)-3-HYDROXY-5-OXO-6-HEPTENOIC ACID

METABOLITE -> PARENT

Qualification:

FECAL

Amount:

7.3 % (average)
of dose


					ULK88EV7VQ

PITAVASTATIN LACTONE

METABOLITE -> PARENT

Qualification:

URINE

Amount:

0.8 % (average)
of dose


					VSZ43HE9FC

(3R,6E)-7-(2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-3-QUINOLINYL)-3-HYDROXY-5-OXO-6-HEPTENOIC ACID

METABOLITE -> PARENT

Qualification:

URINE

Amount:

4.1 % (average)
of dose


					LW7V5ZBK9R

(3R,5S,6E)-7-(2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-8-HYDROXY-3-QUINOLINYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID

METABOLITE -> PARENT

Qualification:

FECAL

Amount:

7.2 % (average)
of dose


					LW7V5ZBK9R

(3R,5S,6E)-7-(2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-8-HYDROXY-3-QUINOLINYL)-3,5-DIHYDROXY-6-HEPTENOIC ACID

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

PLASMA

Amount:

[<1] % (average)
of plasma radioactivity

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					M5681Q5F9P

PITAVASTATIN

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Parameters
Volume of Distribution	PHARMACOKINETIC	2.11 Liters/Kilogram (average)

Biological Half-life	PHARMACOKINETIC	12 hours (average)

Tmax	PHARMACOKINETIC	0.75 hours (average)	ORAL ADMINISTRATION SINGLE DOSE 4 mg (average)